AbstractNeuroblastoma (NB) is an embryonal deadly cancer in childhood driven by MYC or MYCN‐driven oncogenic signaling. The amplification of MYCN leads to malignant progression of NB and poor prognosis. Traditional chemotherapy is still a standard treatment for NB. Most of the cytostatic drugs take function in anti‐neuroblastoma. However, children with NB exhibit different clinical outcome variability and biological characteristics compared to adult patients. Given this, it is an urgent need to explore novel, safer and more efficacious treatments.